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Altered divalent ion metabolism in early renal failure: Role of
1,25(OH)2D. The present study evaluates the role of 1 ,25(OH)2D in the
pathogenesis of abnormal mineral metabolism in patients with early
renal failure (ERF). This was accomplished by examining the calcemic
response to PTH and the handling of an oral phosphate load both before
and after 6 weeks of therapy with 1 ,25(OH)2D. Twelve patients with
ERF and six normal volunteers were studied. Patients with ERF as
compared with normal subjects have low serum phosphate, low urinary
calcium, low serum l,25(OH)2D, and high plasma PTH and urinary
cyclic AMP (cAMP). With EDTA infusion, an impaired calcemic
response to PTH is observed in patients with ERF. The phosphate load
test shows that these patients have an increased ability to excrete
phosphate. After I ,25(OH)2D therapy a significant increase in serum
phosphate, urinary calcium, and a decrease in urinary cAMP is ob-
served only in ERF patients. In addition, the impaired calcemic
response to PTH improves significantly, the renal handling of phos-
phate becomes normal, and the low baseline level of l,25(OH)2D
increases to normal. A significant correlation between levels of
l,25(OH)2D and creatinine clearance is observed in both patients and
normals. In summary, the present data suggest that a mild deficiency of
1 ,25(OH)2D is present in ERF patients. The pathophysiological conse-
quence of such a deficiency in patients with ERF may be important.
Alteration du métabolisme des ions divalents lors de l'insuffisance
rénale précoce: Role du l,25(OH)2D. Cette étude évalue le role du
1 ,25(OH)2D dans la pathogdnie des anormalies du métabolisme mineral
chez des malades en insuffisance rénale précoce (ERF). Cela a été
accompli en examinant Ia rdponse calcémique a Ia PTH et l'dlimination
d'une charge orale en phospates avant et après 6 semaines de traitement
avec le 1 ,25(OH)2D. Douze malades en ERF et six volontaires sains ont
été étudiés. Par rapport aux normaux, les malades en ERF avaient une
phosphatdmie basse, une calciurie basse, un 1 ,25(OH)2D sérique bas et
une PTH plasmatique et un AMP cyclique (cAMP) urinaire élévés. Lors
d'une perfusion d'EDTA, une réponse calcémique anormale a Ia PTH
est observée chez les malades en ERF. Le test de charge en phosphates
montre que ces malades ont une capacité accrue d'excréter des phos-
phates. Après traitement par le I ,25(OH)2D, une augmentation signifi-
cative de la phosphatémie, de Ia calciurie, et une diminution de cAMP
urinaire sont observdes chez les malades en ERF seulement. En outre,
la réponse calcémique anormale a Ia PTH s'amdliore significativement,
l'élimination rénale des phosphates devient normale et le faible niveau
de base de 1 ,25(OH)2D s'élève a Ia normale. Une correlation significa-
tive entre les niveaux de 1 ,25(OH)2D et Ia clearance de la créatinine est
observée chez les malades et les normaux. En résumé, ces données
suggérent qu'un deficit modérd en 1 ,25(OH)2D existe chez les malades
en ERF. La consequence physio-pathologique de ce deficit en ERF
pourrait être importante.
(PTH) are observed in patients with early renal failure (ERF)
[1—4]. The observed secondary hyperparathyroidism is reflected
by increased bone resorption which is already present in the
early stages of renal insufficiency [5].
Although most investigators agree that hypocalcemia is the
initial stimulus for the development of secondary hyperpara-
thyroidism, several factors have been postulated as the cause of
the decreased serum calcium; these include phosphate retention
[6], impaired calcemic response to PTH [2, 4], and altered
vitamin D metabolism [7]. These factors may be interrelated
and it is likely that one factor may exert a more prominent role
than the others at different stages of renal insufficiency.
The importance of a 1,25 dihydroxycholecalciferol [1,25-
(OH)2D1 deficiency in ERF patients has been suggested by
several investigators. Liach et al [8] observed that dietary
phosphate restriction in patients with ERF increases the serum
calcium, improves intestinal absorption of calcium, normalizes
the calcemic response to PTH, and improves bone histology.
They suggested that intermittent elevations in serum phosphate
may impair the production of 1 ,25(OH)2D and that phosphate
restriction improves calcium homeostasis by affecting an
endogenous increase of 1,25(OH)2D synthesis. Portale et al [9]
have shown a 40% reduction in plasma 1 ,25(OH)2D in children
with moderate renal insufficiency. In addition, detailed studies
by Portale et a! [10] in children with ERF placed on a reduced
phosphate diet have shown an increase of 1 ,25(OH)2D synthe-
sis. These data suggest that a mild deficiency of 1 ,25(OH)2D
may contribute to the genesis of hypocalcemia in patients with
ERF. However, this hypothesis has not been tested by examin-
ing whether exogenous administration of 1,25(OH)2D in pa-
tients with ERF increases serum calcium, suppresses PTH
activity, increases intestinal absorption of calcium, and im-
proves the calcemic response to PTH. In addition, the presence
of phosphate retention, another factor alleged to produced
hypocalcemia in ERF, has not been clearly demonstrated.
Therefore, in the present study, we evaluated the role of
1 ,25(OH)2D in the pathogenesis of the abnormal mineral me-
tabolism observed in patients with ERF by examining the
calcemic response to PTH and the handling of an oral phos-
Secondary hyperparathyroidism commonly develops in pa-
tients with chronic failure. Alterations in calcium homeostasis
resulting in increased circulating levels of parathyroid hormone
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phate load before and after 6 weeks of treatment with
1 ,25(OH)D.
Methods
The patient population consisted of 12 male patients, ages 45
to 68 years (mean 60 7), with a stable mean creatinine
clearance of 62 12 mI/mm (range, 38 to 78 ml/min). No patient
had protein excretion greater than 1 g124 hr or evidence of
associated systemic disease. Six healthy volunteers, 22 to 58
years of age (mean, 42 12) with mean creatinine clearances of
112 10 ml/min (101 to 120 ml/min), were also studied. All
subjects remained on their normal diet which was continued for
the course of the study; diuretics were discontinued 1 week
prior to the study. Other medications (such as antihypertensive
drugs) were continued. All studies were performed on an
inpatient metabolic ward and subjects gave signed consent to
the protocol approved by the Institutional Review Board of the
University of Oklahoma Health Sciences Center, Oklahoma
City, Oklahoma, USA.
Prior to treatment with 1 ,25(OH)2D, fasting blood samples for
determination of serum calcium, phosphate, creatinine, and
carboxy terminal PTH (C-PTH) were obtained. Blood samples
for 1 ,25(OH)2D were obtained only in control subjects and in
the last six patients studied. The mean age of these six patients
was 54 6 years. In both patients and control subjects, 24-hr
urine samples were collected for measurement of cyclic AMP
(cAMP), calcium, phosphate, and creatinine.
After baseline studies were completed, an ethylene-diamine-
tetraacetate (EDTA) infusion was performed to assess the
calcemic response to endogenous PTH. Disodium EDTA, 50
mg/kg in 500 cc of 5% dextrose and water, was infused
intravenously in fasting subjects at a constant rate from 8 to 10
AM. Blood was sampled from an indwelling intravenous cath-
eter for determination of plasma nonchelated calcium, serum
phosphate, creatinine, and C-PTH at the following times: zero
time (prior to initiation of infusion), every 30 mm during the
infusion, and at 1, 2, 4, 6, 10, and 22 hr after completion of the
infusion. Nine subjects with ERF and four normal subjects
received the EDTA infusion.
At a minimum of 4 days following the EDTA infusion, an oral
phosphate load was performed after an overnight fast. All
subjects received a 1000 cc water load at 7 AM and 240 cc of
water hourly thereafter. One gram of sodium potassium phos-
phate was administered as a single oral dose at 9 AM. Fasting
blood samples were obtained from an indwelling intravenous
catheter for determination of serum calcium, phosphate, and
creatinine at 8:30 AM and hourly thereafter for 6 hr and at 6 AM
the following day. Urine specimens were collected hourly for
calcium, phosphate, and creatinine. Eight ERF patients and
four controls participated in the phosphate load test.
Following completion of the EDTA infusion and the oral
phosphate load all patients and controls received 1 ,25(OH)2D,
0.25 gig, orally, twice daily at 8 AM and 8 PM for 6 weeks. After
6 weeks of l,25(OH)2D, the baseline studies, including the
EDTA infusion and phosphate loading tests, were repeated.
Calcium, phosphate, and creatinine were measured with
a multichannel autoanalyzer (Technicon Instruments Corp.,
Tarrytown, New York, USA). Nonchelated calcium was de-
termined by EGTA titration utilizing an automated calcium
analyzer (Calcette, Precision System Inc., Sudbury, Massachu-
setts, USA). Creatinine clearance was calculated using a stan-
dard formula. The renal phosphate threshold concentration
(TmPO4/GFR) was determined by the method of Walton and
Bijvoet [11].
Plasma immunoreactive PTH was determined by radio-
immunoassay; the C-PTH was measured with the antibody
GP-5 (at a dilution of 1:100,000). The GP-5 antiserum was
developed by immunization of a guinea pig with purified bovine
PTH. Its major antigenic recognition site on the hormone
molecule is located in the amino acid sequence 35-84 of PTH.
This antibody has shown little reactivity with the amino-
terminal fragment containing the amino acid sequence 1-34 [12].
The details of the radioimmunoassay procedure have been
described elsewhere [131. A highly purified preparation of
bovine PTH [14] was used as a standard and for the preparation
of '251-labeled hormone. This standard has been compared with
the British Medical Research Council bovine PTH standard
(code 7 1/324). On an immunologic basis, 1 mg of our standard is
equivalent to 3000 U of the Medical Research Council standard.
Aliquots of each freshly thawed sample were assayed in quad-
ruplicate, so that the concentration reported for a sample was
the mean of four determinations. The coefficient of variation for
the assay sample was 10 to 12% and interassay variation was
also 10 to 12%. Normal serum PTH values, carboxy terminal, in
our laboratory are 0.1 to 0.5 ng/ml. Urinary cAMP was deter-
mined by standard radioimmunoassay.
Serum I ,25(OH)2D levels were assayed in 3- to 4-ml samples
by the methods of Eisman eta! [15], and Eisman, Shepard, and
DeLuca [16], using a competitive binding assay with cytosol
preparations from rachitic chick duodenum as the source of
binding protein. Serum was extracted with dichioromethane,
chromatographed on Sephadex LH-20 in hexane-chloroform-
methanol (9:1:1), and separated on silicic acid columns using
hexane-iso-propanol (9:1) under high pressure. Recovery of
l,25(OH)2D, determined using [3H1 l,25(OH)2D as an internal
standard, averaged 53.5%; the interassay coefficient of varia-
tion was 11%. In 38 adults, aged 20 to 72 years, the normal
serum l,25(OH)2D concentration ranged from 19 to 50 pg/ml,
mean SD, 32 7.7 pg/ml. No seasonal variation was
observed, and values were similar in both sexes. Blood samples
were drawn at 8 AM; they were measured in triplicate and were
assayed blindly.
Statistical analysis of baseline data was performed with the
Student t test. For observation in the same patient a paired t test
was performed for the changes observed in the same subject
during EDTA and phosphate load tests. In addition, a two-way
analysis of variance was used for data analysis of these tests.
Linear regression analysis was also performed. All results are
expressed as the mean value SE.
Results
Baseline biochemical data in ERF patients and normals
before and after 6 weeks of l,25(OH)2D are shown in Table 1.
Compared to normals, ERF patients prior to treatment with
l,25(OH)2D demonstrated a decreased serum phosphate (P <
0.05), a decreased 24-hr urinary calcium excretion (P < 0.05),
an increased urinary cAMP (P < 0.01), an increased C-PTH (P
< 0.05), and a decreased serum l,25(OH)2D (P < 0.01). The
baseline serum calcium was similar in both groups and the
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Table 1. Baseline chemistry before (B) and after (A) 1 ,25(OH)2D therapya
Serum Serum Plasma Urinary TmPO4/ Urinary cAMP
calcium phosphate C-PTH calcium GFR mmoles/min/
mg/dl mg/dl ng/ml mg/24 hr mg/di 100 cc GFR
Serum
I ,25(OH)2D
pg/mi
Normal subjects
B 8.94 0.2 3.2 0.2 0.34 0.1 194 55 2.7 0.2 1.82 0.2 39 5
A 9.01 0.1 3.3 0.2 0.46 0.1 217 38 3.0 0.4 2.04 0.2 50 11
Patients
B 9.06 0.2 2.6 0.2" 0.52 0.1" 64 10" 2.4 0.2 4.33 Q,4 16 3
A 9.40 0.1" 3.4 0.1" 0.54 0.1 169 23" 2.9 0.1" 2.39 03b 44 7"
a Values (±) presented are the mean SE.
b P < 0.05 patients vs. normal subjects.
P < 0.01.
d p < 0.05 patients before vs. after l,25(OH)2D.
C <0.01.
Table 2. C-PTH and nonchelated calcium during EDTA infusion before (B) and after (A) 1 ,25(OH)2D therapya
Hours 0 2 4 8 12 24
Normal subjects B 0.32 0.1 0.87 0.3 0.45 0.1 0.40 0.2 0.36 0.2 0.32 0.1
C-PTH, ng/ml A 0.45 0.2 0.77 0.2 0.66 0.1 0.50 0.1 0.41 0.5 0.37 0.1
Calcium, mg/dl B 9.05 0.4 6.62 0.2 7.48 0.1 8.24 0.3 8.69 0.3 9.29 0.2
A 9.09 0.1 6.75 0.1 7.64 0.1 8.49 0.1 8.89 0.1 9.43 0.1
Patients B 0.54 0.1" 0.98 0.1 0.80 0.1" 0.83 0.1" 0,82 0.1" 0.75 0.1"
C-PTH, ng/ml A 0.57 0.1 1.05 0.2 0.90 0.1 0.80 0.1 0.79 0.1" 0.65 0.1
Calcium, mg/dl B 9.11 0.1 6.59 0.2 7.22 0.1 7.76 0.1 7.94 01"
A 9.39 0.2 7.01 0.1" 7.68 0.2" 8.23 0.2" 8.43 0.2
8.20 0.2"
8.87 0.1""
a Values are presented as the mean SE.
b P < 0.05 patients vs. normal subjects.
P < 0.01.
d P < 0.05 patients before vs. after I ,25(OH)2D.
P < 0.01.
TmPO4/GFR values were not significantly different in patients
and normal subjects.
Following treatment with 1 ,25(OH)2D significant changes
were observed only in ERF patients, which included an in-
crease in serum calcium (P < 0.01), serum phosphate (P <
0.01), 24-hr urinary calcium excretion (P < 0.01), TmPO4IGFR
(P < 0.05), and serum 1,25(OH)2D (P < 0.01). Urinary cAMP
decreased (P < 0.01) and C-PTH remained unchanged. In both
groups creatinine clearance remained unchanged after treat-
ment with 1,25(OH)2D.
In Table 2, the C-PTH and nonchelated calcium in both
normal subjects and patients during EDTA infusion before and
after 1,25(OH)2D therapy are presented. In Figure 1 the signifi-
cant differences during the EDTA infusion in normal subjects
and ERF patients prior to l,25(OH)2D are displayed. Basal
C-PTH was significantly elevated in ERF patients as compared
to normals (P < 0.05). During EDTA-induced hypocalcemia
C-PTH increased rapidly in both groups. The highest level of
C-PTH was observed on completion of the EDTA infusion;
thereafter, C-PTH declined slowly and returned to baseline
levels in normals at 24 hr. At almost all concentrations of
nonchelated calcium the level of C-PTH was significantly higher
in ERF patients than in normals. The baseline values of
nonchelated calcium prior to the EDTA infusion were not
different for the two groups (Table 2). The nadir of EDTA-
induced hypocalcemia was similar in both groups. In normal
subjects, the calcium level at 24 hr returned to the pre-infusion
level while in ERF patients, nonchelated calcium at 12 and 24 hr
were significantly lower than the pre-infusion level (P < 0.01).
In addition, the calcium concentration at 12 (P < 0.05) and 24 (P
<0.01) hr was lower in ERF patients than normal subjects. This
occurred despite higher levels of PTH in ERF patients.
In Figure 2, in patients with ERF, the levels of calcium and
PTH during EDTA infusion before and after administration of
l,25(OH)2D were compared; after l,25(OH)2D administration
the calcium level was significantly higher at almost every
interval. Although the baseline level of calcium before the
EDTA infusion increased following I ,25(OH)2D, the magnitude
of the EDTA-induced hypocalcemia (change from basal value
to post infusion nadir, 2-hr value) was similar before and after
l,25(OH)2D (2.5 0.1 vs. 2.4 0.1 mg!dl). However, the
calcemic recovery (difference between nadir calcium and 24-hr
postinfusion calcium) significantly increased from 1.6 0.1 to
1.9 0.1 mg/dl following l,25(OH)2D (P < 0.01). The nonche-
lated calcium value was also significantly higher at 12 and 24 hr
postinfusion following I ,25(OH)2D. The serum calcium value at
12 hr was no longer significantly different from normals (Table
2); however, after l,25(OH)2D, the calcium value in ERF
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Fig. 1. Mean values (± SE) ofPTH and nonchelated calcium in relation
to time during and after the infusion of ethylenediamine-tetra-acetate
(EDTA) prior to 1,25(OH)2D therapy. The open circles represent values
from patients with early renal failure. The open triangles represent
values from normal subjects. Symbols are: ', P < 0.05; , P < 0.01.
patients at 24 hr remained significantly lower than normals at 24
hr and lower than the preinfusion value.
In ERF patients, the PTH response to the EDTA-induced
hypocalcemia was not altered with 1 ,25(OH)2D therapy. In the
normal subjects, the serum calcium and PTH response during
EDTA infusion did not change before and after 6 weeks of
1 ,25(OH)2D (Table 2).
In Table 3, the serum phosphate and TmPO4/GFR values in
both normal subjects and patients during the phosphate load
test both before and after the administration of 1 ,25(OH)2D are
presented. Figure 3 shows the effects of the phosphate load
prior to 1 ,25(OH)2D therapy in ERF patients compared with
normal subjects; serum phosphate and TmPO4/GFR were lower
at nearly every interval in ERF patients. However, significant
differences in serum phosphate were observed only after 5 (P <
0.01) and 6 hr (P < 0.05). Likewise, the TmPO4/GFR was
significantly lower only after 5 (P < 0.05) and 6 hr (P < 0.01).
Figure 4 shows the phosphate load before and after
1 ,25(OH)2D therapy in ERF patients. A significantly higher
serum phosphate level is observed at nearly every interval.
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Fig. 2. Mean values (± SE) ofPTH and nonchelated calcium during the
EDTA test in patients before (open circles) and after (closed circles)
1,25(OH)2D3 therapy. Symbols are: * P < 0.05; °', P < 0.01.
Likewise, the TmPO4IGFR increased after 1 ,25(OH)2D, but the
increment was significant only at baseline (P < 0.05) and alter
3 (P < 0.05) and 6 hr (P < 0.05).
In normal subjects, no significant changes in serum phos-
phate and TmPO4IGFR occurred with the phosphate load
following l,25(OH)2D (Table 3). In addition, the differences
noted prior to I ,25(OH)2D therapy between normal subjects
and patients during the phosphate load test are no longer
present (Fig. 5). Thus, alter 1 ,25(OH)2D administration, serum
phosphate and TmPO4/GFR values in ERF patients were com-
parable to normal subjects.
Since 1 ,25(OH)2D is known to increase intestinal phosphate
absorption, urinary phosphate excretion after the phosphate
load was measured as an index of intestinal phosphate absorp-
tion. Thus the 6-hr urinary phosphate was compared to basal
values both before and after 1 ,25(OH)2D. The 6-hr cumulative
increment was obtained by subtracting the basal phosphate
values from the 6-hr urinary phosphate values. In ERF patients
the 6-hr cumulative increment augmented from 25 10 mg
before to 66 15 mg alter 1,25(OH)2D (P < 0.05). In normals
the 6-hr cumulative increment did not change after 1 ,25(OH)2D,
69 21 vs. 74 23 mg, respectively.
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Hours 0 1 2 3 6 24
Normal subjects
Phosphate, mg/dl B
A
3.08 0.1
3.33 0.1
3.28 0.2
3.55 0.1
3.58 0.2
3.90 0.1
3.83 0.2
3.80 0.1
3.97 0.1
3.70 0.2
3.50 0.1
3.16 0.1
TmPO4/GFR, mgldl B
A
2.84 0.3
2.85 0.2
2.73 0.3
2.88 0.2
2.50 0.2
2.68 0.2
2.71 0.3
2.74 0.1
3.11 0.2
2.69 0.2
Patients
Phosphate, mg/dl B
A
2.79 0.2
3.33 0.la
3.25 0.2
4.63 0.2a
3.61 0.1
4.08 0.la
3.48 0.1
4.01 0.l'
3.50 0.lC
3.64 0.1
3.16 0.1
3.48 0.la
TmPOIdI, mg/dl B
A
2.41 0.2
2.93 o.la
2.55 0.3
2.72 0.1
2.33 0.2
2.96 0.2
2.30 0.2
2.73 0.la
2.16 02d
2.50 o.la
a P < 0.05 patients before vs. after 1,25(OH)2D.
b P < 0.01.
P < 0.05 patients vs. normal subjects.
P <0.01.
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There was a significant correlation (P < 0.001) between
creatinine clearance and 1 ,25(OH)2D among patients with ERF
and normal subjects (Fig. 6).
Discussion
The present study documents significant abnormalities in
both divalent ion metabolism and parathyroid gland function
during the early stages of renal insufficiency. These include a
low serum phosphate, low urinary calcium excretion, an eleva-
tion in plasma C-PTH and urinary cAMP, and an impaired
calcemic response to endogenous PTH. Moreover, patients
with ERF have an increased and not a decreased ability to
excrete phosphate. After 1,25(OH)2D treatment, increases in
serum calcium, phosphate, and 24-hr urinary calcium excretion
are observed only in ERF patients; the impaired calcemic
response to PTH improves and the renal handling of phosphate
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Fig. 3. Mean values (±sE) of serum phosphate and
TmPO4IGFR in patients with early renal failure
(open circles) and normal subjects (open triangles)
during the phosphate load test, prior to 1,25(OH)2D
therapy. ', P <0.05; **, P < 0.01.
Fig. 4. Mean values (±s) of serum phosphate and
TmPO4/GFR during the phosphate load test in
patients with early renal failure before (open circles)
and after (closed circles) l,25(OH)2D therapy.
Symbols are: ', P < 0.05; ', P < 0.01.
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Fig. 6. A comparison of serum l,25(OH)2D values with the creatinine
clearances in both patients (open circles) and normal subjects (closed
circles).
becomes normal. Low levels of 1,25(OH)2D are present in ERF
patients and a significant correlation between levels of
1,25(OH)2D and creatinine clearance is obtained.
Though there are no significant differences in the mean
baseline serum calcium values between patients and normal
subjects, an increase in serum calcium after l,25(OH)2D is
observed only in ERF patients. This finding agrees with short-
and long-term administration of l,25(OH)2D in patients with
advance chronic renal failure [18—20]. Healy et al [21] treated
three ERF patients with l,25(OH)2D, 0.5 pg/day, for 6 months
and observed an increase in serum and urinary calcium, and a
decrease in PTH. Conversely, little effect has been observed on
the serum calcium of normal subjects receiving 1 ,25(OH)2D
[22]. The low serum phosphate observed in ERF patients
confirm previous studies [4, 8, 23] and suggest that hyperphos-
phatemia may not be the only factor in the genesis of secondary
hyperparathyroidism. The low TmPO4/GFR indicates that an
increase in phosphate excretion most likely due to hyperpara-
thyroidism may be responsible for the low serum phosphate
levels. A significant increase in both serum phosphate levels
and TmPO4/GFR after 1 ,25(OH)2D is observed only in patients
with ERF; this suggests that an increase in tubular reabsorption
of phosphate contributes to the increase in serum phosphate.
The mechanism leading to an increase in tubular phosphate
reabsorption may be either a decrease in PTH activity or a
direct action of l,25(OH)2D at the renal tubule. A decrease in
PTH activity was not reflected by a decrease in the PTH levels.
However, the decrement in urinary cAMP observed only in
ERF patients after I ,25(OH)2D suggests a reduction in PTH
biological activity. Because urinary cAMP reflects the func-
tional end-organ activity of PTH at the renal tubule, it should
theoretically be a better indicator of the biological activity of
PTH than direct measurement of PTH. In addition, the 24-hr
urine value of cAMP reflects hormonal activity throughout the
day while basal levels of PTH may not [171. The elevated
baseline levels of urinary cAMP agree with previous studies [4].
Krensky et al [24] have observed that elevated levels of urinary
cAMP occur in ERF and accurately reflect the presence of
secondary hyperparathyroidism. Another theoretical possibility
is that at this moderately elevated PTH concentration, the
radioimmunoassay may not recognize a mild decrement in
hormone levels. Raisz et al [25] emphasized the problems in
measuring mild PTH elevations with the currently available
radioimmunoassays. A direct action of l,25(OH)2D on tubular
phosphate reabsorption is also possible. The experimental data
in animals [261 and in healthy humans [27] are not clear, and
data on the tubular effects of 1 ,25(OH)2D in ERF patients are
not available.
The low urinary calcium excretion observed in our patients
has been observed by other investigators and attributed to the
excess of PTH and its hypocalciuric effect [28]. Likewise, the
increment in urinary calcium after l,25(OH)2D observed only in
ERF patients may also reflect a decrease in PTH biological
activity. It is likely that an increased intestinal absorption of
calcium leads to an increment in serum calcium, which results
in increased calcium excretion.
The absence of significant hypercalciuria after 1 ,25(OH)2D in
normal subjects does not agree with previous studies [29].
However, these studies have been either of shorter duration or
have used larger dosages [30, 311. Another possibility is that
dietary intake of calcium may have varied in our normal
subjects. Maierhofer et al [31] have shown the importance of
dietary calcium in urinary calcium excretion in normal subjects
receiving 1 ,25(OH)2D.
The mean serum concentration of 1 ,25(OH)2D in ERF pa-
tients was low and significantly different from normals. Prelimi-
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nary observations of normal 1 ,25(OH)2D levels in patients with
serum creatinine from 1.5 to 3.5 mg/dl have been previously
reported [32]. More recent and detailed studies by Portale et al
[91 have observed a 40% reduction in 1 ,25(OH)2D levels in
children with moderate renal insufficiency. Chesney et al [33]
have also reported low levels of 1 ,25(OH)2D in patients with
creatinine clearances below 48 mI/mm and normal levels in
patients with creatinine clearances above 75 ml/min. Likewise,
Juttman et al [34] have observed subnormal levels of
1 ,25(OH)2D in patients with creatinine clearances between 40
and 50 mI/mm. Our patients have creatinine clearances between
50 and 80 mllmin, a range not studied by the previous investiga-
tors. The production of 1,25(OH)2D by the kidney is related to
the functional state of proximal renal tubules and since glomer-
ular filtration rate (GFR) presumably reflects functional renal
mass, a decrement in l,25(OH)2D may occur slowly and pro-
gressively as GFR declines. Recent observations by Kawaguchi
et al [35] in the rat have shown a progressive decrease in renal
synthesis of 1 ,25(OH)2D following graded nephron mass reduc-
tion. Finally, since patients with ERF were older than control
subjects, age conceivably may be a factor in the lower levels of
1 ,25(OH)2D observed in these patients [36].
With sterol therapy, the magnitude of the increment in
1,25(OH)2D in ERF patients, is greater than in normal subjects.
The reason for this is not apparent. One may speculate that the
relationship between 1,25(OH)2D and 24,25(OH)2D in ERF
patients may be different from normal subjects and may account
for such differences. In children with mild renal failure,
Chesney et al [33] have observed a direct correlation between
these two sterols, and it may be possible that such a correlation
may be shifted in patients with ERF. Thus, in normal subjects,
administration of l,25(OH)2D may result with an increased
endogenous production of 24,25(OH)2D, thereby not changing
the levels of 1,25(OH)2D. In ERF patients administration of
l,25(OH)2D may not produce a shift in synthesis to
24,25(OH)2D until circulating 1 ,25(OH)2D reach levels compa-
rable to normal.
In ERF, the EDTA infusion confirms the presence of a
decreased calcemic response to PTH [4], and an improvement
with l,25(OH)2D therapy. The magnitude of the hypocalcemia
is similar before and after l,25(OH)2D; however, the difference
between nadir calcium and 24-hr postinfusion serum calcium is
significantly increased in ERF patients while no change is
observed in normal subjects. This suggests that the presence of
normal levels of I ,25(OH)2D in ERF patients may have im-
proved the calcemic response to PTH; a relative deficiency of
this sterol may be important in the decreased calcemic response
to PTH. The administration of 1 ,25(OH)2D to nephrectomized
dogs significantly improved the calcemic response to PTH [37].
Maierhofer et al [30] have shown that 1 ,25(OH)2D in addition to
PTH plays an important role in bone resorption in humans.
Prior to 1,25(OH)2D administration, during the phosphate
load test, the serum phosphate and TmPO4/GFR in ERF
patients are lower at nearly every hour as compared with
normal subjects. Thus, phosphate retention in the early stages
of renal insufficiency is not present in these patients. According
to Slatopolsky et al [6], phosphate retention plays the major role
in the pathogenesis of secondary hyperparathyroidism. Fur-
thermore, to explain the hypophosphatemia observed by vari-
ous investigators, they suggested that postprandial hyperphos-
phatemia occurs which then stimulates PTH secretion and thus
leads to low fasting serum phosphate levels [38]. The present
data do not support this hypothesis because they show that
patients with ERF have an increased ability to excrete phos-
phate. These data are consistent with recent findings; Portale et
al [9] in five hypophosphatemic children with ERF were unable
to detect changes in serum phosphate in the postprandial
period. Massry, Ritz, and Verberckmoes [39] studied the effect
of a I -g phosphate load in six normal subjects and eight patients
with ERF; they observed a comparable increase in serum
phosphate in patients and normal subjects. The exaggerated
phosphate excretion and lower serum phosphorus levels ob-
served in our patients are different from those of Massry, Ritz,
and Verberckmoes [39], which most likely reflects the lesser
renal impairment in our patients. The level of renal function
apparently determines the response to a phosphate load; with
more advanced renal insufficiency, Maschio et al [40] observed
an impaired phosphate excretion after the same oral phosphate
load. Of interest is that patients with ERF given a phosphate
load excrete phosphate in a manner similar to patients with
primary hyperparathyroidism [41].
In ERF patients, the administration of 1,25(OH)2D results in
a dramatic change in the response to a phosphate load. After
l,25(OH)2D therapy, patients with ERF respond to the phos-
phate load similar to normal subjects. The higher levels of
serum phosphate as compared with levels prior to I ,25(OH)2D
therapy may be the result either of a decreased biological
activity of PTH or a direct action of the sterol on tubular
reabsorption of phosphate. The former possibility is supported
by the observed decrease in urinary cAMP. The latter is
theoretically possible, though in normal subjects, I ,25(OH)2D
does not produce changes in tubular reabsorption [27]. An
alternative explanation may be an increase in intestinal absorp-
tion of phosphate. Both in humans and the rat, 1 ,25(OH)2D
increases intestinal absorption of phosphate [42, 43]. The aug-
mentation in the 6-hr cumulative increment of urinary phos-
phate observed only in ERF patients suggests an increase in
intestinal absorption of phosphate as a consequence of
1 ,25(OH)2D administration.
The present data suggest that a mild deficiency of 1 ,25(OH)2D
is present in ERF and may mediate the abnormal divalent
mineral homeostasis. The cause of this deficiency is not yet
defined. Portale et al [9] postulated that in ERF an increase in
the intracellular concentration of phosphate in the proximal
tubule as the result of increased urinary excretion of phosphate
may occur; this in turn will reduce the activity of 1
cw-hydroxylase and decrease synthesis of l,25(OH)2D. Consist-
ent with this hypothesis is our previous observations that four
ERF patients placed on phosphate restriction had a decrease in
phosphate excretion, an increase in intestinal absorption of
phosphate, and a decrease in PTH. Additional studies from
Portale et al [10] in children with ERF placed on a reduced
phosphate diet have shown an increase synthesis of 1,25(OH)2D
despite a decrease in PTH. These findings were associated with
a significant decrease in the fractional excretion of phosphate.
Regardless of the cause for a decrease in the concentration of
1 ,25(OH)2D, the pathophysiological consequence of such a
deficiency in patients with ERF may be important.
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